Citius Pharmaceuticals, Inc. (47N0)
XMUN 
NASDAQ (CM) Primary XMUN Summary
Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today?
Citius Pharmaceuticals (NASDAQ: CTXR ) stock is on the rise Tuesday after the company announced new results from its Phase 3 clinical trial of Mino-Lok. Mino-Lok is Citius Pharmaceuticals' antibiotic lock solution for patients with central line-associated infections or catheter-related bloodstream infections.
Citius Pharmaceuticals, Inc. (47N0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Citius Pharmaceuticals, Inc. ever had a stock split?
Citius Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Leonard L. Mazur CEO | XMUN Exchange | US17322U3068 ISIN |
| US Country | 23 Employees | 9 Jun 2017 Last Dividend | 26 Nov 2024 Last Split | 6 Jul 2017 IPO Date |
Overview
Citius Pharmaceuticals, Inc. is a late-stage pharmaceutical company specialized in developing and commercializing critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Since its foundation in 2007, Citius has concentrated on addressing unmet medical needs through a robust pipeline of proprietary products. It embarks on creating innovative solutions in the healthcare space, aiming to improve the lives of patients dealing with severe diseases. Headquartered in Cranford, New Jersey, Citius is dedicated to progressing its clinical trials to bring groundbreaking therapies to market.
Products and Services
- LYMPHIR: An engineered IL-2 diphtheria toxin fusion protein designed for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. LYMPHIR is at the forefront of Citius's oncology pipeline, currently in a Phase 3 clinical trial, aiming to provide a novel therapeutic option for a challenging form of cancer.
- Mino-Lok: An antibiotic lock solution aimed at treating patients with catheter-related bloodstream infections by salvaging the infected catheter. Mino-Lok, now in Phase 3 clinical trial, represents Citius’s approach to combating serious infections and reducing the need for catheter replacements.
- Halo-Lido: A corticosteroid-lidocaine topical formulation in a clinical Phase 2b trial. This product is designed to offer anti-inflammatory and anesthetic relief for individuals suffering from hemorrhoids, showcasing Citius’s commitment to addressing common yet often neglected conditions.
- Mino-Wrap: A liquifying gel-based wrap intended for the reduction of tissue expander infections following breast reconstructive surgeries. Mino-Wrap exemplifies Citius’s dedication to improving postoperative outcomes and enhancing the quality of care in reconstructive surgery.
- NoveCite: A mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. NoveCite represents Citius’s foray into the burgeoning field of cell therapy, emphasizing the company’s commitment to pioneering treatments for critical care and respiratory diseases.
